×
About 51,064 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  24,159 results

Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI r...
https://doi.org/10.1158/1078-0432.CCR-20-3679
Clinical Cancer Research : an Official Journal of the Ame... Makela E, Pavic K et. al.

Mar 6th, 2021 - Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56a. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2Asplicing variant, NOCIVA (NOvel CIp2a VAriant). Charac...

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction...
https://doi.org/10.1097/FPC.0000000000000431
Pharmacogenetics and Genomics; Megías-Vericat JE, Martínez-Cuadrón D et. al.

Mar 6th, 2021 - Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway (CBR3: rs1056892, rs8133052, NQO1: rs18...

Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
https://doi.org/10.1038/s41589-021-00742-5 10.1056/NEJMra1406184 10.1182/blood.V124.21.437.437 10.1182/blood-2009-05-222034 10.1182/blood-2013-07-513044 10.1182/blood-2019-124034 10.1182/blood.V128.22.102.102 10.1002/ajh.23308 10.1517/13543784.17.11.1623 10.1073/pnas.122233699 10.1007/s10147-007-0694-6 10.1038/sj.leu.2402807 10.1182/blood-2017-10-813139 10.1016/j.cub.2003.09.024 10.1158/0008-5472.CAN-17-1240 10.1021/acs.jmedchem.8b01469 10.1038/sj.emboj.7601675 10.1016/j.pharmthera.2017.02.027 10.1038/s41392-019-0101-6 10.1016/j.ccell.2019.10.002 10.1021/cb200519y 10.1038/nchembio.2538 10.1021/acs.jmedchem.9b00871 10.1016/j.bmcl.2019.03.035 10.1016/j.chembiol.2018.11.006 10.1002/anie.201901336 10.1016/j.ejmech.2019.111952 10.1021/jm050267e 10.1158/0008-5472.CAN-05-0882 10.1016/j.bmcl.2006.04.071 10.1038/nrc.2017.103 10.1016/j.ddtec.2019.01.002 10.1038/nchembio.2329 10.1038/s41589-018-0055-y 10.1016/j.chembiol.2017.09.010 10.4161/cc.4.8.1918 10.4049/jimmunol.1202313 10.1038/srep21664 10.1002/eji.200425154 10.1084/jem.20172246 10.1073/pnas.1905221116 10.1006/excr.2001.5200 10.1158/0008-5472.CAN-09-1947 10.1371/journal.pone.0168387 10.1038/s41467-019-09234-6 10.1093/nar/gky869 10.1016/j.gpb.2017.01.001 10.1093/nar/gkz1210
Nature Chemical Biology; Wang L, Shao X et. al.

Mar 5th, 2021 - The discovery of effective therapeutic treatments for cancer via cell differentiation instead of antiproliferation remains a great challenge. Cyclin-dependent kinase 2 (CDK2) inactivation, which overcomes the differentiation arrest of acute myeloi...

The prognostic value of the peripheral blood cell counts changes during induction chemo...
https://doi.org/10.1097/MD.0000000000024614
Medicine Huang YM, Wang YN et. al.

Mar 5th, 2021 - To investigate the prognostic value of the circulating peripheral blood cell counts changes in acute myeloid leukemia (AML) at different time points during induction chemotherapy.We retrospectively analyzed the clinical and laboratory data of 237 ...

see more →

Guidelines  95 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/

May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...

AMG 330 Shows Promise in Treating Relapsed/Refractory AML
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml

May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...

High Expression of DOCK2 Indicates Good Prognosis in AML
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N,et al

Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).

see more →

Drugs  59 results see all →

Clinicaltrials.gov  25,251 results

Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI r...
https://doi.org/10.1158/1078-0432.CCR-20-3679
Clinical Cancer Research : an Official Journal of the Ame... Makela E, Pavic K et. al.

Mar 6th, 2021 - Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56a. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2Asplicing variant, NOCIVA (NOvel CIp2a VAriant). Charac...

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction...
https://doi.org/10.1097/FPC.0000000000000431
Pharmacogenetics and Genomics; Megías-Vericat JE, Martínez-Cuadrón D et. al.

Mar 6th, 2021 - Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway (CBR3: rs1056892, rs8133052, NQO1: rs18...

Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
https://doi.org/10.1038/s41589-021-00742-5 10.1056/NEJMra1406184 10.1182/blood.V124.21.437.437 10.1182/blood-2009-05-222034 10.1182/blood-2013-07-513044 10.1182/blood-2019-124034 10.1182/blood.V128.22.102.102 10.1002/ajh.23308 10.1517/13543784.17.11.1623 10.1073/pnas.122233699 10.1007/s10147-007-0694-6 10.1038/sj.leu.2402807 10.1182/blood-2017-10-813139 10.1016/j.cub.2003.09.024 10.1158/0008-5472.CAN-17-1240 10.1021/acs.jmedchem.8b01469 10.1038/sj.emboj.7601675 10.1016/j.pharmthera.2017.02.027 10.1038/s41392-019-0101-6 10.1016/j.ccell.2019.10.002 10.1021/cb200519y 10.1038/nchembio.2538 10.1021/acs.jmedchem.9b00871 10.1016/j.bmcl.2019.03.035 10.1016/j.chembiol.2018.11.006 10.1002/anie.201901336 10.1016/j.ejmech.2019.111952 10.1021/jm050267e 10.1158/0008-5472.CAN-05-0882 10.1016/j.bmcl.2006.04.071 10.1038/nrc.2017.103 10.1016/j.ddtec.2019.01.002 10.1038/nchembio.2329 10.1038/s41589-018-0055-y 10.1016/j.chembiol.2017.09.010 10.4161/cc.4.8.1918 10.4049/jimmunol.1202313 10.1038/srep21664 10.1002/eji.200425154 10.1084/jem.20172246 10.1073/pnas.1905221116 10.1006/excr.2001.5200 10.1158/0008-5472.CAN-09-1947 10.1371/journal.pone.0168387 10.1038/s41467-019-09234-6 10.1093/nar/gky869 10.1016/j.gpb.2017.01.001 10.1093/nar/gkz1210
Nature Chemical Biology; Wang L, Shao X et. al.

Mar 5th, 2021 - The discovery of effective therapeutic treatments for cancer via cell differentiation instead of antiproliferation remains a great challenge. Cyclin-dependent kinase 2 (CDK2) inactivation, which overcomes the differentiation arrest of acute myeloi...

The prognostic value of the peripheral blood cell counts changes during induction chemo...
https://doi.org/10.1097/MD.0000000000024614
Medicine Huang YM, Wang YN et. al.

Mar 5th, 2021 - To investigate the prognostic value of the circulating peripheral blood cell counts changes in acute myeloid leukemia (AML) at different time points during induction chemotherapy.We retrospectively analyzed the clinical and laboratory data of 237 ...

see more →

News  1,493 results

FDA Places Clinical Hold on Sickle Cell Gene Therapy
https://www.medscape.com/viewarticle/946434

Feb 23rd, 2021 - Updated February 25, 2021 // Editor’s note: The original text has been corrected to accurately reflect the status of the patients with AML and MDS. The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) a...

Fast Five Quiz: Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943967

Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...

Leukemia: New Adverse Event With PARP Inhibitors in Cancer
https://www.medscape.com/viewarticle/943743

Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate.   PARP inhibitors are...

Black Race Linked to Poorer Survival in AML
https://www.medscape.com/viewarticle/942309

Dec 8th, 2020 - Black race is the most important risk factor for patients with acute myeloid leukemia (AML) and is associated with poor survival, according to new findings. Among patients with AML younger than 60 years, the rate of overall 3-year survival was sig...

Beat AML: Precision Medicine Superior to SOC
https://www.medscape.com/viewarticle/940843

Nov 11th, 2020 - Precision medicine therapy proved feasible and superior to standard-of-care (SOC) chemotherapy in patients with acute myeloid leukemia in the Beat AML Master Clinical Trial. The 30-day mortality rates were 3.7% versus 20.4% in 224 patients who enr...

see more →

Patient Education  7 results see all →